Literature DB >> 10089904

Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein.

S Bowen1, N Tare, T Inoue, M Yamasaki, M Okabe, I Horii, J F Eliason.   

Abstract

Proteins conjugated with polyethylene glycol (PEG) have increased in vivo activity compared to native proteins. We examined the activity of a variety of PEG conjugates prepared with a recombinant mutein of granulocyte colony-stimulating factor (nartograstim [NTG], KW-2228). The total PEG mass was varied by the number and size of the PEG molecules conjugated. In vitro activity, determined using a proliferation assay with G-NFS-60 cells, demonstrated an inverse relationship between PEG mass and concentration required for half-maximal proliferation. In vivo activity was examined by injecting compounds subcutaneously into normal mice and determining neutrophil counts at various times. Initial experiments in C57BL/6J mice indicated that neutrophil levels were significantly elevated 5 days after a single injection of 25 micrograms/mouse of each PEG-NTG preparation. More detailed experiments were performed with several of the preparations in C3H/HeJ mice lacking endotoxin receptors. The results demonstrated that the time after injection at which neutrophil numbers reached a maximum increased with increasing size of PEG. Similar results were obtained with purified preparations containing 1, 2, or 3 units of 20-kDa PEG per molecule of NTG, showing that increasing the extent of PEGylation also increases in vivo activity. Dose-response studies with the 20-kDa PEG-NTG demonstrated a plateau at doses > 2.7 micrograms/mouse at day 3. The plateau dose increased to 8.4 micrograms/mouse at day 5, and no plateau was evident at the highest dose tested (50 micrograms/mL) at days 7 and 10. These results demonstrate that elevated neutrophil levels can be maintained for extended periods following single administration of high-molecular-weight PEG-NTG.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10089904     DOI: 10.1016/s0301-472x(98)00051-4

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  11 in total

Review 1.  Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Site-Specific Protein PEGylation: Application to Cysteine Analogs of Recombinant Human Granulocyte Colony-Stimulating Factor.

Authors:  Mary S Rosendahl; Daniel H Doherty; Darin J Smith; Alison M Bendele; George N Cox
Journal:  Bioprocess Int       Date:  2005-04

3.  De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: report of a case.

Authors:  Kazuki Takeishi; Ken Shirabe; Takeo Toshima; Toru Ikegami; Kazutoyo Morita; Takasuke Fukuhara; Takashi Motomura; Yohei Mano; Hideaki Uchiyama; Yuji Soejima; Akinobu Taketomi; Yoshihiko Maehara
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

4.  Synthesis and characterization of PEGylated toll like receptor 7 ligands.

Authors:  Michael Chan; Tomoko Hayashi; Richard D Mathewson; Shiyin Yao; Christine Gray; Rommel I Tawatao; Kevin Kalenian; Yanmei Zhang; Yuki Hayashi; Fitzgerald S Lao; Howard B Cottam; Dennis A Carson
Journal:  Bioconjug Chem       Date:  2011-02-21       Impact factor: 4.774

5.  Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity.

Authors:  Nian Gong; Ai-Niu Ma; Li-Jie Zhang; Xiao-Su Luo; Yin-Hui Zhang; Michael Xu; Yong-Xiang Wang
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

6.  A new direction for anticoagulants: inhibiting fibrin assembly with PEGylated fibrin knob mimics.

Authors:  Sarah E Stabenfeldt; Nader M Aboujamous; Allyson S C Soon; Thomas H Barker
Journal:  Biotechnol Bioeng       Date:  2011-04-26       Impact factor: 4.530

7.  Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture.

Authors:  Megan E Fox; Francis C Szoka; Jean M J Fréchet
Journal:  Acc Chem Res       Date:  2009-08-18       Impact factor: 22.384

8.  Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC).

Authors:  Sam-Mui Tsui; Wai-Man Lam; Tin-Lun Lam; Hiu-Chi Chong; Pui-Kin So; Sui-Yi Kwok; Simon Arnold; Paul Ning-Man Cheng; Denys N Wheatley; Wai-Hung Lo; Yun-Chung Leung
Journal:  Cancer Cell Int       Date:  2009-04-17       Impact factor: 5.722

Review 9.  Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor.

Authors:  Tara Arvedson; James O'Kelly; Bing-Bing Yang
Journal:  BioDrugs       Date:  2015-06       Impact factor: 5.807

10.  Hematopoietic properties of granulocyte colony-stimulating factor/immunoglobulin (G-CSF/IgG-Fc) fusion proteins in normal and neutropenic rodents.

Authors:  George N Cox; Elizabeth A Chlipala; Darin J Smith; Sharon J Carlson; Stacie J Bell; Daniel H Doherty
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.